Vasculitis Treatment Guidelines

Initial Management

For non-organ threatening vasculitis, oral prednisone 1 mg/kg/day (up to 80 mg/day) is recommended, with the initial dose maintained for 1 month before tapering, and not reduced below 15 mg/day during the first 3 months, as per the European League Against Rheumatism (EULAR) guidelines 1
The American College of Rheumatology (ACR) recommends adding steroid-sparing agents like methotrexate (15-25 mg/week) or mycophenolate mofetil for mild recurrent/persistent disease, and considering alternative options, including rituximab, especially for ANCA-positive vasculitis 2

For organ-threatening/severe vasculitis, IV methylprednisolone (Solumedrol) 500-1000 mg/day for 3-5 days is recommended, followed by oral prednisone 1 mg/kg/day, and combined with cyclophosphamide or rituximab for ANCA-associated vasculitis, as per EULAR guidelines 3
Methylprednisolone is specifically recommended in vasculitis treatment protocols by EULAR and ACR guidelines due to its better tissue penetration and intermediate duration of action 1

Prophylaxis against Pneumocystis jiroveci is recommended for patients on cyclophosphamide, as per EULAR guidelines 1
Cardiovascular risk should be assessed periodically, as per EULAR guidelines 3
Glucocorticoids should be tapered to the lowest effective dose to minimize toxicity, with a recommended initial prednisone regimen of 1 mg/kg/day (generally up to 80 mg/day) for initial treatment, followed by a gradual taper over several months, according to the American College of Rheumatology 4, 5, 1
The tapering schedule should be as follows:
Patients should be monitored for common steroid-related adverse effects, including blood pressure, blood glucose, weight changes, mood alterations, and signs of infection, and assessed for new lesions and healing of existing lesions every 1-2 weeks during initial treatment 4, 5
For chronic or relapsing disease, consider adding steroid-sparing agents, such as azathioprine (2 mg/kg/day) or methotrexate (up to 25 mg/week), as suggested by the European League Against Rheumatism, and cyclophosphamide for severe or refractory disease, as recommended by the American College of Rheumatology 4, 5, 1
Treatment failure is defined as continued disease activity despite 3 weeks of prednisone at 1 mg/kg/day, according to the British Association of Dermatologists 6